---
title: "Cardiovascular outcomes of GLP-1 receptor agonists: systematic review findings"
id: "pubmed-42033237"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42033237"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42033237/"
doi: "10.1093/ajhp/zxag121"
published_at: "2026-11-10T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Cardiovascular outcomes of GLP-1 receptor agonists: systematic review findings
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42033237
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42033237/)
- **DOI:** [10.1093/ajhp/zxag121](https://doi.org/10.1093%2Fajhp%2Fzxag121)
- **Published At:** 2026-11-10T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The authors performed a systematic review identifying 12 randomized cardiovascular outcome trials of **GLP1RAs** across several patient populations, including those with and without **type 2 diabetes**. - Ten trials enrolled patients with **type 2 diabetes**; one enrolled people with overweight/obesity plus ASCVD but without diabetes; one enrolled patients with obesity and HFpEF (with or without diabetes). - Drug delivery varied: eight trials used weekly subcutaneous injections; two trials used once-daily oral **semaglutide**; the source did not report all individual dosing regimens in this abstract. - Follow-up across trials ranged from 1.2 to 5.4 years, according to the abstract. - Pooled signals showed a consistent reduction in **MACE** among patients with **type 2 diabetes** treated with GLP1RAs, investigators reported. - The effect on cardiovascular death and all-cause mortality was less certain overall; only **liraglutide** demonstrated reductions in MACE, cardiovascular death, and all-cause death in its trial, per the review. - In patients with overweight/obesity and ASCVD (without diabetes), weekly **semaglutide** lowered risk of **MACE** but did not lower cardiovascular death, the authors observed. - In patients with obesity and HFpEF (with or without diabetes), **tirzepatide** lowered the composite endpoint of adverse heart-failure events and cardiovascular death, according to the abstract. - Most trials were judged to have low risk of bias. The review noted that gastrointestinal adverse events were a common reason for discontinuation across trials. - The source concluded that GLP1RA therapy lowers **MACE** in patients with **type 2 diabetes** and reported cardiovascular benefit signals in two non‑T2D populations, while leaving uncertainty about mortality benefits. - The abstract did not provide full trial-level methodological details (for example, precise dosing schedules and individual trial endpoint definitions) in the summary text available here; readers should consult the full text for granular trial methods.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42033237/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42033237%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42033237/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42033237/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42033237/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42033237/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42033237/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42033237/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42033237%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42033237%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42033237/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42033237/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42033237/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42033237/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Silverchair Information Systems full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--academic.oup.com-images-oup_pubmed_free.png) Silverchair Information Systems ](https://academic.oup.com/ajhp/article-lookup/doi/10.1093/ajhp/zxag121 "See full text options at Silverchair Information Systems") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42033237/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42033237/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42033237/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42033237/#abstract) * [ Figures ](https://pubmed.ncbi.nlm.nih.gov/42033237/#figures) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42033237/#similar) * [ References ](https://pubmed.ncbi.nlm.nih.gov/42033237/#references) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42033237/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42033237/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42033237/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42033237/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42033237/#linkout) Title & authors Abstract Figures Similar articles References Publication types MeSH terms Substances Related information LinkOut - more resources Am J Health Syst Pharm Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Am+J+Health+Syst+Pharm%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Am+J+Health+Syst+Pharm%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42033237/) . 2026 Nov 10;83(22):1216-1229. doi: 10.1093/ajhp/zxag121. # Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review [Nicoline Bihelek](https://pubmed.ncbi.nlm.nih.gov/?term=Bihelek+N&cauthor_id=42033237)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42033237/#full-view-affiliation-1 "Jim Pattison Outpatient Care and Surgery Centre, Lower Mainland Pharmacy Services, Surrey, BC, Canada."), [Sarah Burke](https://pubmed.ncbi.nlm.nih.gov/?term=Burke+S&cauthor_id=42033237)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42033237/#full-view-affiliation-2 "Gordon and Leslie Diamond Health Care Centre, Lower Mainland Pharmacy Services, Vancouver, BC, Canada."), [Arden R Barry](https://pubmed.ncbi.nlm.nih.gov/?term=Barry+AR&cauthor_id=42033237)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42033237/#full-view-affiliation-3 "Jim Pattison Outpatient Care and Surgery Centre, Lower Mainland Pharmacy Services, Surrey, BC.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42033237/#full-view-affiliation-4 "Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada.") Affiliations Expand ### Affiliations * 1 Jim Pattison Outpatient Care and Surgery Centre, Lower Mainland Pharmacy Services, Surrey, BC, Canada. * 2 Gordon and Leslie Diamond Health Care Centre, Lower Mainland Pharmacy Services, Vancouver, BC, Canada. * 3 Jim Pattison Outpatient Care and Surgery Centre, Lower Mainland Pharmacy Services, Surrey, BC. * 4 Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada. * PMID: **42033237** * PMCID: [ PMC13747719 ](https://pmc.ncbi.nlm.nih.gov/articles/PMC13747719/) * DOI: [ 10.1093/ajhp/zxag121 ](https://doi.org/10.1093/ajhp/zxag121) Item in Clipboard # Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review Nicoline Bihelek et al. Am J Health Syst Pharm. 2026. Show details Display options Display options Format Abstract PubMed PMID Am J Health Syst Pharm Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Am+J+Health+Syst+Pharm%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Am+J+Health+Syst+Pharm%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42033237/) . 2026 Nov 10;83(22):1216-1229. doi: 10.1093/ajhp/zxag121. ### Authors [Nicoline Bihelek](https://pubmed.ncbi.nlm.nih.gov/?term=Bihelek+N&cauthor_id=42033237)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42033237/#short-view-affiliation-1 "Jim Pattison Outpatient Care and Surgery Centre, Lower Mainland Pharmacy Services, Surrey, BC, Canada."), [Sarah Burke](https://pubmed.ncbi.nlm.nih.gov/?term=Burke+S&cauthor_id=42033237)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42033237/#short-view-affiliation-2 "Gordon and Leslie Diamond Health Care Centre, Lower Mainland Pharmacy Services, Vancouver, BC, Canada."), [Arden R Barry](https://pubmed.ncbi.nlm.nih.gov/?term=Barry+AR&cauthor_id=42033237)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42033237/#short-view-affiliation-3 "Jim Pattison Outpatient Care and Surgery Centre, Lower Mainland Pharmacy Services, Surrey, BC.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42033237/#short-view-affiliation-4 "Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada.") ### Affiliations * 1 Jim Pattison Outpatient Care and Surgery Centre, Lower Mainland Pharmacy Services, Surrey, BC, Canada. * 2 Gordon and Leslie Diamond Health Care Centre, Lower Mainland Pharmacy Services, Vancouver, BC, Canada. * 3 Jim Pattison Outpatient Care and Surgery Centre, Lower Mainland Pharmacy Services, Surrey, BC. * 4 Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada. * PMID: **42033237** * PMCID: [ PMC13747719 ](https://pmc.ncbi.nlm.nih.gov/articles/PMC13747719/) * DOI: [ 10.1093/ajhp/zxag121 ](https://doi.org/10.1093/ajhp/zxag121) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract **Purpose:** To identify and evaluate cardiovascular outcome trials for glucagon-like peptide-1 receptor agonists (GLP1RAs) in various patient populations, including those with or without type 2 diabetes (T2D). **Summary:** A systematic search of MEDLINE identified 12 cardiovascular outcome-based randomized controlled trials: 10 in patients with T2D, one in patients with overweight/obesity and atherosclerotic cardiovascular disease (ASCVD) but not T2D, and one in patients with obesity and heart failure with preserved ejection fraction (HFpEF). Most trials had a low risk of bias. The GLP1RA was administered as a weekly subcutaneous injection in 8 trials, and 2 trials used once-daily oral semaglutide. Follow-up ranged from 1.2 to 5.4 years. GLP1RA therapy showed a consistent reduction in major adverse cardiovascular events (MACE) in patients with T2D. The effect on cardiovascular and all-cause death was less certain. Individually, only liraglutide demonstrated a reduction in MACE, cardiovascular death, and all-cause death. In patients with overweight/obesity and ASCVD (but without T2D), weekly subcutaneous semaglutide lowered the risk of MACE but not cardiovascular death. In patients with obesity and HFpEF (with or without T2D), tirzepatide lowered the occurrence of the composite endpoint of adverse heart failure events and cardiovascular death. Discontinuation of GLP1RA therapy due to gastrointestinal adverse events was common across the trials. **Conclusion:** These data support the use of GLP1RAs to lower MACE in patients with T2D. A cardiovascular benefit with GLP1RA therapy was also observed in 2 additional patient populations: those with overweight/obesity and ASCVD but without T2D and those with obesity and HFpEF with or without T2D. **Keywords:** cardiovascular diseases; diabetes mellitus, type 2; glucagon-like peptide-1 receptor agonists; heart failure, preserved ejection fraction; obesity. © American Society of Health-System Pharmacists 2026. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Figures [ ![Figure 1.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d42/13747719/a3415e3f2492/zxag121f1.gif) ](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d42/13747719/cc5f305d240b/zxag121f1.webp) ** Figure 1. ** Preferred Reporting Items for Systematic… ** Figure 1. ** Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flow diagram. MACE indicates… **Figure 1.** Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flow diagram. MACE indicates major adverse cardiovascular events; RCT, randomized controlled trial. [ ![Figure 2.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d42/13747719/4571e1d9a454/zxag121f2.gif) ](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d42/13747719/c1eef6ce3057/zxag121f2.webp) ** Figure 2. ** Graphical abstract. This systematic review… ** Figure 2. ** Graphical abstract. This systematic review of cardiovascular (CV) outcome trials showed that glucagon-like… **Figure 2.** Graphical abstract. This systematic review of cardiovascular (CV) outcome trials showed that glucagon-like peptide-1 receptor agonists (GLP1RAs) reduced major adverse CV events in patients with type 2 diabetes (T2D) or overweight/obesity (but without diabetes) who are at high CV risk, as well as patients with obesity and heart failure with preserved ejection fraction (HFpEF). ASCVD indicates atherosclerotic cardiovascular disease; BMI, body mass index; HF, heart failure; MACE, major adverse cardiovascular events; MI, myocardial infarction; RCT, randomized controlled trial; RAASi, renin-angiotensin-aldosterone system inhibitor; SC, subcutaneous; SGLT2i, sodium-glucose cotransporter 2 inhibitor. [See this image and copyright information in PMC](https://pubmed.ncbi.nlm.nih.gov/42033237/) ## Similar articles * [ Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. ](https://pubmed.ncbi.nlm.nih.gov/39222642/) Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, Emerson SS, Kahn SE, Kitzman DW, Lingvay I, Mahaffey KW, Petrie MC, Plutzky J, Rasmussen S, Rönnbäck C, Shah SJ, Verma S, Weeke PE, Lincoff AM; SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Trial Committees and Investigators.Kosiborod MN, et al.Lancet. 2024 Sep 7;404(10456):949-961. doi: 10.1016/S0140-6736(24)01643-X. Epub 2024 Aug 30.Lancet. 2024.PMID: 39222642Clinical Trial. * [ Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. ](https://pubmed.ncbi.nlm.nih.gov/39181597/) Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, Lingvay I, Colhoun HM, Plutzky J, Kosiborod MN, Hovingh GK, Hardt-Lindberg S, Frenkel O, Weeke PE, Rasmussen S, Goudev A, Lang CC, Urina-Triana M, Pietilä M, Lincoff AM; SELECT Trial Investigators.Deanfield J, et al.Lancet. 2024 Aug 24;404(10454):773-786. doi: 10.1016/S0140-6736(24)01498-3.Lancet. 2024.PMID: 39181597Clinical Trial. * [ Impact of glucagon-like peptide-1 receptor agonism-based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta-analysis. ](https://pubmed.ncbi.nlm.nih.gov/41424191/) Dutta D, Mahajan K, Kamrul-Hasan ABM, Mahajan N, Sharma M, Vohra S.Dutta D, et al.Diabetes Obes Metab. 2026 Mar;28(3):2075-2084. doi: 10.1111/dom.70391. Epub 2025 Dec 22.Diabetes Obes Metab. 2026.PMID: 41424191 * [ Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials. ](https://pubmed.ncbi.nlm.nih.gov/40156846/) Lee MMY, Sattar N, Pop-Busui R, Deanfield J, Emerson SS, Inzucchi SE, Mann JFE, Marx N, Mulvagh SL, Poulter NR, Badve SV, Pratley RE, Perkovic V, Buse JB, McGuire DK; SOUL Trial Investigators.Lee MMY, et al.Diabetes Care. 2025 May 1;48(5):846-859. doi: 10.2337/dc25-0241.Diabetes Care. 2025.PMID: 40156846 * [ Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis. ](https://pubmed.ncbi.nlm.nih.gov/41761267/) Shokravi A, Seth J, Mancini GBJ.Shokravi A, et al.Cardiovasc Diabetol. 2026 Feb 27;25(1):115. doi: 10.1186/s12933-026-03113-3.Cardiovasc Diabetol. 2026.PMID: 41761267Free PMC article. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42033237) ## References 1. 1. Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA.. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361–71. doi: 10.1016/j.jacc.2022.11.005 - [DOI](https://doi.org/10.1016/j.jacc.2022.11.005) 2. 1. Martin SS, Aday AW, Allen NB, et al. ; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Committee. 2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2025;151(8):e41–e660. doi: 10.1161/CIR.0000000000001303 - [DOI](https://doi.org/10.1161/cir.0000000000001303) 3. 1. Ussher JR, Drucker DJ.. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463–474. doi: 10.1038/s41569-023-00849-3 - [DOI](https://doi.org/10.1038/s41569-023-00849-3) 4. 1. Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105–113. doi: 10.1016/S2213-8587(17)30412-6 - [DOI](https://doi.org/10.1016/s2213-8587\(17\)30412-6) 5. 1. Lee MMY, Sattar N, Pop-Busui R, et al. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials. Diabetes Care. 2025;48(5):846–859. doi: 10.2337/dc25-0241 - [DOI](https://doi.org/10.2337/dc25-0241) Show all 32 references ## Publication types * Systematic Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Systematic+Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Systematic+Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42033237/) ## MeSH terms * Cardiovascul
## Related Clinical Research

- [Compare and Contrast: GLP-1 Receptor Agonists Access and Cardiovascular Outcomes](https://medichelpline.com/clinical-feed/endocrine-news-33-compare-and-contrast-as-glucagon-like-peptide-1-receptor-agonist-access-expands-comparative-heart-outcomes-matter.md)
- [GLP-1 drugs tied to lower diabetes progression and cardiovascular events than metformin](https://medichelpline.com/clinical-feed/aha-news-4-glp-1-meds-linked-to-lower-diabetes-heart-risks-than-standard-diabetes.md)
- [Semaglutide and Primary Prevention of MACCE in Obese Adults with T2DM and Rheumatoid Arthritis](https://medichelpline.com/clinical-feed/pubmed-42334436.md) (DOI: 10.1093/ehjcvp/pvag044)
- [Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do](https://medichelpline.com/clinical-feed/endocrine-news-34-beyond-the-scale-what-else-glucagon-like-peptide-1-receptor-agonists-can-do.md)
- [Tirzepatide in Older Adults with Type 2 Diabetes: Real-World Hypoglycemia and Weight Outcomes](https://medichelpline.com/clinical-feed/pubmed-42457543.md) (DOI: 10.1507/endocrj.EJ26-0246)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.